Breaking News Instant updates and real-time market news.

NBIX

Neurocrine

$45.00

-1.58 (-3.39%)

, TEVA

Teva

$44.56

-0.48 (-1.07%)

06:27
10/12/16
10/12
06:27
10/12/16
06:27

Neurocrine recent selloff a buying opportunity, says Leerink

Leerink analyst Paul Matteis views the 18% pullback in shares of Neurocrine Biosciences (NBIX) over the past few weeks as a buying opportunity. The analyst finds the catalyst for the selloff "difficult to pinpoint," but notes he's been receiving questions from investors on the size of the market opportunity for vesicular monoamine transporters in Tardive Dyskinesia. A doctor survey suggests a target market of 300,000 TD patients for Neurocrine's and Teva's VMAT2 inhibitors, which is enough to offer a "significant revenue opportunity" for both drugs, Matteis tells investors in a research note. Further, the analyst believes the upcoming Phase II data in Tourette's Syndrome, which he sees as having a high probability of success, offers a "nice catalyst for investors" into Q1 of next year. Matteis reiterates an Outperform rating on Neurocrine with a $70 price target.

NBIX

Neurocrine

$45.00

-1.58 (-3.39%)

TEVA

Teva

$44.56

-0.48 (-1.07%)

  • 06

    Nov

  • 15

    Nov

  • 14

    Dec

NBIX Neurocrine
$45.00

-1.58 (-3.39%)

06/29/16
HCWC
06/29/16
INITIATION
Target $80
HCWC
Buy
Neurocrine initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein started Neurocrine Biosciences with a Buy rating and $80 price target.
09/23/16
LEER
09/23/16
NO CHANGE
LEER
Outperform
Positive data paves way for Teva SD-809 indication, says Leerink
Leerink analyst Jason Gerberry says the AIM-TD study readout clinically de-risks Teva's (TEVA) SD-809 opportunity for tardive dyskinesia, with the investor focus shifting to market size and competitive differentiation versus Neurocrine's (NBIX) valbenazine. The analyst believes Teva's SD-809 is well positioned to compete against valbenazine with an equally efficacious and well tolerated drug. Further, he expects Teva to exit 2017 with a broader label. Gerberry reiterates an Outperform rating on Teva's shares.
10/04/16
LEER
10/04/16
INITIATION
Target $70
LEER
Outperform
Neurocrine reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of Neurocrine with an Outperform rating and $70 price target.
10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.
TEVA Teva
$44.56

-0.48 (-1.07%)

10/05/16
WELS
10/05/16
NO CHANGE
WELS
Outperform
Teva estimates lowered on generic trends at Wells Fargo
Wells Fargo analyst David Maris lowered his estimates for Teva (TEVA) for this year and next, citing expectations for lower generic sales this year and lower margins in the generic business. Maris lowered his price target range for Teva shares to $60-$61 from $70-73 based on his lower estimates as well as the uncertainty of the environment, but keeps an Outperform rating on shares citing valuation and his belief 2017 should be a better year with several pipeline events for Teva.
10/06/16
WELS
10/06/16
NO CHANGE
WELS
Wells calls Teva partnership with Celltrion 'good news'
Wells Fargo analyst David Maris views Teva Pharmaceutical's partnership to commercialize two of Celltrion's monoclonal antibody biosimilar candidates as "good news." Teva is now a "little more firmly in the biosimilar game," Maris tells investors in a research note. He likes that the initial cash outflow is small and the partner. Maris has an Outperform rating on Teva.
10/07/16
LEER
10/07/16
NO CHANGE
Target $57
LEER
Outperform
Teva price target lowered to $57 from $61 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva to $57 from $61 and trimmed his estimates to reflect near-term headwinds and a more conservative Copaxone outlook. The analyst continues to view a generic Copaxone launch in late the second half of 2017 as a risk. Nonetheless, Gerberry reiterates an Outperform rating on the stock as he views shares as attractively valued despite near-term EPS concerns and believes investor attention will eventually pivot to Teva's attractive late stage pipeline.
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.

TODAY'S FREE FLY STORIES

AZN

AstraZeneca

$32.81

-0.12 (-0.36%)

07:31
09/22/17
09/22
07:31
09/22/17
07:31
Upgrade
AstraZeneca rating change  »

AstraZeneca upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 08

    Nov

SXT

Sensient

$75.90

0.19 (0.25%)

07:30
09/22/17
09/22
07:30
09/22/17
07:30
Initiation
Sensient initiated  »

Sensient initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRVL

Marvell

, CAR

Avis Budget

$38.08

0.16 (0.42%)

07:30
09/22/17
09/22
07:30
09/22/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

MRVL

Marvell

CAR

Avis Budget

$38.08

0.16 (0.42%)

GIS

General Mills

$51.69

-0.48 (-0.92%)

FINL

Finish Line

$9.22

-0.21 (-2.23%)

HOG

Harley-Davidson

$47.96

-0.39 (-0.81%)

JBLU

JetBlue

$18.90

-0.35 (-1.82%)

MXWL

Maxwell

$4.97

-0.155 (-3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 02

    Oct

  • 05

    Oct

  • 17

    Oct

  • 08

    Nov

TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

, S

Sprint

07:29
09/22/17
09/22
07:29
09/22/17
07:29
Periodicals
T-Mobile, Sprint close to agreeing on deal terms, Reuters reports »

T-Mobile (TMUS) and…

TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

S

Sprint

DTEGY

Deutsche Telekom

$18.36

-0.39 (-2.08%)

SFTBF

SoftBank

$81.50

-1.14 (-1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 16

    May

EADSY

Airbus

$23.07

0.78 (3.50%)

, BA

Boeing

$256.04

0.58 (0.23%)

07:29
09/22/17
09/22
07:29
09/22/17
07:29
Periodicals
Turkish Airlines mulls Airbus order following Boeing deal, Reuters reports »

Turkish Airlines has…

EADSY

Airbus

$23.07

0.78 (3.50%)

BA

Boeing

$256.04

0.58 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

, VSAR

Versartis

$21.60

-0.25 (-1.14%)

07:28
09/22/17
09/22
07:28
09/22/17
07:28
Recommendations
Ascendis Pharma, Versartis analyst commentary  »

Ascendis Pharma price…

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

07:28
09/22/17
09/22
07:28
09/22/17
07:28
Hot Stocks
Trump says greatest influence over election was 'Fake News Media' »

President Donald Trump…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

, S

Sprint

07:27
09/22/17
09/22
07:27
09/22/17
07:27
Periodicals
Breaking Periodicals news story on T-Mobile, Sprint, Deutsche Telekom, SoftBank »

T-Mobile, Sprint close to…

TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

S

Sprint

DTEGY

Deutsche Telekom

$18.36

-0.39 (-2.08%)

SFTBF

SoftBank

$81.50

-1.14 (-1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 16

    May

FB

Facebook

$171.11

-1.06 (-0.62%)

07:26
09/22/17
09/22
07:26
09/22/17
07:26
Hot Stocks
Trump says Russia 'hoax' now onto Facebook ads »

President Donald Trump…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

07:25
09/22/17
09/22
07:25
09/22/17
07:25
General news
FX Update: »

FX Update: USD-JPY dove…

JNJ

Johnson & Johnson

$131.75

-1.47 (-1.10%)

07:24
09/22/17
09/22
07:24
09/22/17
07:24
Conference/Events
FDA PDUFA Date for Janssen Biotech, a Johnson & Johnson company, Sirukumab »

Janssen Biotech, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

  • 27

    Sep

  • 17

    Oct

KBH

KB Home

$20.78

0.07 (0.34%)

07:24
09/22/17
09/22
07:24
09/22/17
07:24
Recommendations
KB Home analyst commentary  »

KB Home forward estimates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

CUB

Cubic

$46.80

0.6 (1.30%)

07:23
09/22/17
09/22
07:23
09/22/17
07:23
Upgrade
Cubic rating change  »

Cubic upgraded to Strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$65.60

-0.19 (-0.29%)

07:21
09/22/17
09/22
07:21
09/22/17
07:21
Conference/Events
FDA PDUFA Date for Merck's sBLA for KEYTRUDA is September 22, 2017 »

Merck's anti-PD-1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

  • 08

    Nov

  • 30

    Nov

GOOG

Alphabet

$932.45

0.87 (0.09%)

, GOOGL

Alphabet Class A

$947.55

0.01 (0.00%)

07:21
09/22/17
09/22
07:21
09/22/17
07:21
Periodicals
Google, partners to issue refunds to advertisers over fake traffic, WSJ reports »

Google is planning to…

GOOG

Alphabet

$932.45

0.87 (0.09%)

GOOGL

Alphabet Class A

$947.55

0.01 (0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 29

    Nov

JNJ

Johnson & Johnson

$131.75

-1.47 (-1.10%)

07:21
09/22/17
09/22
07:21
09/22/17
07:21
Recommendations
Johnson & Johnson analyst commentary  »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

  • 27

    Sep

  • 17

    Oct

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

, VSAR

Versartis

$21.60

-0.25 (-1.14%)

07:18
09/22/17
09/22
07:18
09/22/17
07:18
Recommendations
Ascendis Pharma, Versartis analyst commentary  »

Ascendis Pharma price…

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MA

MasterCard

$141.72

-0.52 (-0.37%)

07:17
09/22/17
09/22
07:17
09/22/17
07:17
Recommendations
MasterCard analyst commentary  »

MasterCard price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

BP

BP

$37.70

0.47 (1.26%)

, SLB

Schlumberger

$68.09

0.47 (0.70%)

07:17
09/22/17
09/22
07:17
09/22/17
07:17
Conference/Events
Federal Reserve Banks of Dallas and Kansas City hold a conference »

2017 Energy Conference:…

BP

BP

$37.70

0.47 (1.26%)

SLB

Schlumberger

$68.09

0.47 (0.70%)

GS

Goldman Sachs

$231.29

1.5 (0.65%)

PAA

Plains All American

$21.72

-0.33 (-1.50%)

CLR

Continental Resources

$37.66

-0.15 (-0.40%)

CHK

Chesapeake

$4.17

-0.02 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 02

    Oct

  • 02

    Oct

  • 03

    Oct

  • 17

    Oct

  • 20

    Oct

  • 22

    Oct

  • 08

    Nov

GOOG

Alphabet

$932.45

0.87 (0.09%)

, GOOGL

Alphabet Class A

$947.55

0.01 (0.00%)

07:14
09/22/17
09/22
07:14
09/22/17
07:14
Periodicals
Google had planned a multimillion Garden Bridge donation, FT says »

Google (GOOG, GOOGL) was…

GOOG

Alphabet

$932.45

0.87 (0.09%)

GOOGL

Alphabet Class A

$947.55

0.01 (0.00%)

AAPL

Apple

$153.39

-2.68 (-1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 29

    Nov

VCRA

Vocera

$29.59

0.42 (1.44%)

07:12
09/22/17
09/22
07:12
09/22/17
07:12
Recommendations
Vocera analyst commentary  »

Vocera checks show…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

XPER

Xperi

$24.75

-0.05 (-0.20%)

07:11
09/22/17
09/22
07:11
09/22/17
07:11
Conference/Events
Xperi management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

WMC

Western Asset Mortgage

$10.66

0.11 (1.04%)

07:10
09/22/17
09/22
07:10
09/22/17
07:10
Conference/Events
Western Asset Mortgage management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

VERI

Veritone

$53.70

7.57 (16.41%)

07:09
09/22/17
09/22
07:09
09/22/17
07:09
Conference/Events
Veritone management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 16

    Nov

EFX

Equifax

$98.25

2.25 (2.34%)

07:09
09/22/17
09/22
07:09
09/22/17
07:09
Upgrade
Equifax rating change  »

Equifax upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.